Cargando…
Elicitation of health state utilities associated with the mode of administration of drugs acting on the prostacyclin pathway in pulmonary arterial hypertension
INTRODUCTION: Pulmonary arterial hypertension (PAH) is a rare, incurable disease associated with decreased life expectancy and a marked impact on quality of life (QoL). There are three classes of drugs available for treatment: endothelin receptor antagonists (ERA), drugs acting on nitric oxide pathw...
Autores principales: | Davies, Evan W, Llewellyn, Samuel, Beaudet, Amélie, Kosmas, Charlotte E, Gin-Sing, Wendy, Doll, Helen A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016589/ https://www.ncbi.nlm.nih.gov/pubmed/29950821 http://dx.doi.org/10.2147/PPA.S160662 |
Ejemplares similares
-
A Health State Utility Study to Elicit Societal Values Associated with Pulmonary Hypertension
por: Nafees, Beenish, et al.
Publicado: (2023) -
Practical considerations for therapies targeting the prostacyclin pathway
por: Farber, Harrison W., et al.
Publicado: (2016) -
Use of prostacyclin in pulmonary hypertension
por: Vicente, R, et al.
Publicado: (1998) -
Role of prostacyclin in pulmonary hypertension
por: Mitchell, Jane A., et al.
Publicado: (2014) -
Clinical and genetic associations with prostacyclin response in pulmonary arterial hypertension
por: Halliday, Stephen J., et al.
Publicado: (2018)